A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Dispenzieri A, Kastritis E, Wechalekar AD, Schönland SO, Kim K, Sanchorawala V, Landau HJ, Kwok F, Suzuki K, Comenzo RL, Berg D, Liu G, Kumar A, Faller DV, Merlini G.
Dispenzieri A, et al. Among authors: faller dv.
Leukemia. 2022 Jan;36(1):225-235. doi: 10.1038/s41375-021-01317-y. Epub 2021 Jun 24.
Leukemia. 2022.
PMID: 34168284
Free PMC article.
Clinical Trial.